Website update in progress

Following the transformation of Polpharma Biologics (learn more), this site will focus on biosimilars development in Switzerland. In Poland, we operate now as Rezon Bio – a contract developer and manufacturer of biologics (CDMO). More at www.rezonbio.com.

Due to the demerger of Polpharma Biologics into two independent companies (detailed information can be found in the “Knowledge center” section), the website polpharmabiologics.com is currently being updated. For details on the CDMO business, please visit the Rezon Bio website

Bioceros develops monoclonal antibodies as a division of Polpharma Biologics Group

Dr. Louis Boon, Chief Scientific Officer of Bioceros (division of Polpharma Biologics Group), talked about Bioceros CHOBC® own platform and explains how SPOT & SLIM technology boost specific productivity and make the process more efficient.

Speaking at BIO-Europe® 2019 in Hamburg, Dr. Boon cited two recent partnerships, one with Sandoz for commercialization of a Natalizumab biosimilar, and an agreement with Coherus. Bioceros’ services are available on a modular basis, fully adjustable to clients’ requests, working together with Polpharma Biologics to offer a truly integrated biopharmaceutical one-stop-shop approach.

For more information, listen to an interview with Dr. Louis Boon:

Watch full video here

Related news

Other news related to this topic that may be of interest to you